Shares of healthcare distributor Cencora (NYSE:COR) jumped 4.5% in the afternoon session after peer company McKesson raised its long-term earnings growth outlook, boosting investor sentiment across the pharmaceutical distribution sector.

The move appeared to be driven by positive developments from rival pharmaceutical distributor McKesson. During its Investor Day event, McKesson announced an increase in its long-term Adjusted Earnings per Diluted Share growth target to a range of 13% to 16%, up from a previous estimate of 12% to 14%. This optimistic forecast from a major industry player seemed to lift investor confidence for the entire sector, suggesting favorable business conditions that could also benefit Cencora.

After the initial pop the shares cooled down to $302.08, up 4.6% from previous close.

Is now the time to buy Cencora? Access our full analysis report here, it’s free.

Cencora’s shares are not very volatile and have only had 1 move greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

Cencora is up 34.4% since the beginning of the year, and at $302.08 per share, it is trading close to its 52-week high of $304.58 from May 2025. Investors who bought $1,000 worth of Cencora’s shares 5 years ago would now be looking at an investment worth $3,209.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.